September 2022 FDA Recall Drug by Quva Pharma, Inc.
D-1544-2022 - Incorrect Product Formulation

This Class III drug recall was voluntarily initiated by Quva Pharma, Inc. on September 20, 2022 for the product Drug. The FDA reported the reason for recall as incorrect product formulation. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1544-2022

Reason for Recall
Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).
Initiated
09-20-2022
Reported
10-05-2022
Quantity
1994 bags

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Nationwide in the USA
oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride, Injection for IV Use, High Alert, This is a Compounded Product for Institutional or Office Use Only, Not for Resale, QuVa PHARMA 519 Route 173, Bloomsbury, NJ 08804, Total volume: 500 mL bag, NDC: 70092-1068-07.

Batch or Lot Expiration Information

Lot# Lot 30027403, BUD 11/14/2022